Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.
Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.

Start Date01 Jan 2025

Sponsor / Collaborator

Peking University Third Hospital

NCT06546384

/ Not yet recruitingNot Applicable

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that liraglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis.
In this study, the investigators aim to assess if patients treated with liraglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.

Start Date01 Jan 2025

Sponsor / Collaborator

Insel Gruppe AG

NCT06361238

/ RecruitingPhase 3IIT

Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: a Single-Center Randomized Controlled Study

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

Start Date19 Nov 2024

Sponsor / Collaborator

Nanjing Drum Tower Hospital

100 Clinical Results associated with Liraglutide

100 Translational Medicine associated with Liraglutide

100 Patents (Medical) associated with Liraglutide

4,280

Literatures (Medical) associated with Liraglutide

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

Author: Dardouri, Mouna ; Nair, Kavita V. ; DiStefano, Michael J. ; Moore, Gina D. ; Saseen, Joseph J.

BackgroundHigh prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.MethodsWe conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.ResultsWe identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.ConclusionThis study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

01 Mar 2025·Metabolism

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

Article

Author: Fragakis, Nikolaos ; Patoulias, Dimitrios ; Mantzoros, Christos S ; Karakasis, Paschalis

BACKGROUND AND AIMSWhile glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain. This meta-analysis evaluated the effects of GLP-1RAs and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs) on body composition, focusing on total weight, fat mass, and lean mass in adults with diabetes and/or overweight/obesity.METHODSA systematic search of Medline, Embase, and the Cochrane Library was conducted through November 12, 2024. Data were analyzed using random-effects pairwise and network meta-analyses to compare interventions with placebo or active comparators.RESULTSTwenty-two randomized controlled trials (2258 participants) were included. GLP-1RAs significantly reduced total body weight (MD -3.55 kg, 95 %-CI [-4.81, -2.29]), fat mass (MD -2.95 kg, 95 %-CI [-4.11, -1.79]), and lean mass (MD -0.86 kg, 95 %-CI [-1.30, -0.42]), with lean mass loss comprising approximately 25 % of the total weight loss. However, the relative lean mass, defined as percentage change from baseline, was unaffected. Liraglutide, at 3.0 mg weekly or 1.8 mg daily, was the only GLP-1RA to achieve significant weight reduction without significantly reducing lean mass. Tirzepatide (15 mg weekly) and semaglutide (2.4 mg weekly) were the most effective for weight and fat mass reduction but were among the least effective in preserving lean mass.CONCLUSIONSPotent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass.

01 Mar 2025·Bone

Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials

Review

Author: Yang, Donghui ; Zhang, Yuan ; Jing, Yali ; Wang, Weimin ; Chen, Guanhua ; Zhu, Dalong

BACKGROUNDType 2 diabetes mellitus (T2DM) is associated with an increased risk of osteoporosis (OP) and fractures.PURPOSEThe aim of this study was to analyze the available evidence on the effect of GLP-1 RAs on fracture risk in patients with type 2 diabetes.METHODSA systematic search based on PubMed, Embase and Web of Science databases was performed to collect relevant literature published until May 2024 on the application of GLP-1 RAs in T2DM patients. Data were extracted from each study for comparative analysis, and meta-analysis was performed using R software to calculate relative risk (RR) and 95 % confidence intervals (CI) for dichotomous variables. Two subgroup analyses were also performed.RESULTSA total of 44 randomized controlled trials (RCTs) involving 47,823 patients were analyzed. There were 292 incident fracture cases (138 in GLP-1 RAs group and 154 in control group). The pooled RR for fractures in patients treated with GLP-1RAs compared with those treated with placebo or other anti-diabetic drugs was 0.77 (95 % CI: 0.61-0.96). Subgroup analyses showed that the beneficial effect was dependent on the period of treatment with GLP-1 RAs, only treated for >78 weeks were effective in reducing the risk of fractures in patients with T2DM (RR 0.77; 95 % CI: 0.61-0.96). Furthermore, subgroup analyses showed that liraglutide treatment was associated with a significant reduction in fracture risk (RR 0.42; 95 % CI: 0.21-0.85). However, other GLP-1 RAs did not present benefits over other anti-diabetic drug treatments.CONCLUSIONGLP-1 RAs could reduce the risk of fracture in T2DM patients, and the beneficial effect was interrelated to the period of treatment. Liraglutide could significantly reduce the risk of fracture in T2DM patients compared to placebo and other anti-diabetic drugs. Due to the limited nature of contemporary research, further studies are needed to develop a clear clinical consensus.

216

News (Medical) associated with Liraglutide

14 Jan 2025

·www.prnewswire.com

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance Q4 2024 revenue is expected to be approximately $13.5 billion, approximately $400 million below the low end of recently issued financial guidance The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year. The company also shared 2025 revenue guidance, anticipating sales will be between $58.0 billion and $61.0 billion. For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro® and $1.9 billion for Zepbound®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and neuroscience medicines in Q4 of 2024. In total, non-incretin revenue grew by 20% compared to Q4 2023. However, the company's expected 2024 revenue is $400 million, or about 3%, below the guidance range issued on October 30, 2024, as part of the Q3 2024 earnings call. "While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results. We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4," said David A. Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca®, Ebglyss™, Omvoh® and Kisunla™; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets, as well as potential launches of new medicines such as imlunestrant for metastatic breast cancer. Incretin market and channel dynamics have been factored into the 2025 revenue guidance range. "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 with strong financial and operational performance," continued Ricks. "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect a continuation of that trend into 2025. We'll also bring additional manufacturing capacity online and expect to produce at least 60% more salable doses of incretins in the first half of the year compared to the first half of 2024." As announced previously, Ricks will participate in a fireside chat at the J.P. Morgan Healthcare Conference later today at 5:15 p.m. Eastern time. A live audio webcast of Ricks' discussion will be available on the "Webcasts & Presentations" section of Lilly's Investor website at . A replay of the presentation will be available on this same website for approximately 30 days. The company currently plans to share its full Q4 2024 financial results, including with respect to other metrics included in its financial guidance, and 2025 financial guidance on February 6, 2025. Preliminary Information The unaudited financial information presented in this press release is preliminary and may change as a result of, among other factors, Lilly's financial closing procedures and as a result, the company's final results may vary materially from the preliminary results included in this press release. The preliminary financial information included in this press release reflects the company's current estimates based on information available as of the date of this press release and has been prepared by company management. This preliminary information should not be viewed as a substitute for full financial information prepared in accordance with GAAP and is not necessarily indicative of the results to be achieved for any future periods. This preliminary information could be impacted by the effects of financial closing procedures, final adjustments, and other developments. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains management's current intentions and expectations for the future, including with respect to Lilly's anticipated 2024 results and 2025 guidance, and specific product performance and supply, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "anticipate", "may", "could", "will", "continue", and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the financial closing procedures, final adjustments, and other developments, significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting the company's products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; safety or efficacy concerns associated with the company's products; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and an increasingly consolidated supply chain; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products, and risks from the proliferation of counterfeit or illegally compounded products; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities; reliance on third-party relationships and outsourcing arrangements; the use of artificial intelligence or other emerging technologies in various facets of the company's operations which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade disruptions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; fluctuations in foreign currency exchange rates or changes in interest rates and inflation; litigation, investigations, or other similar proceedings involving past, current, or future products or activities; changes in tax law and regulations, tax rates, or events that differ from our assumptions related to tax positions; regulatory changes and developments; regulatory actions regarding the company's operations and products; regulatory compliance problems or government investigations; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; asset impairments and restructuring charges; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release. The U.S. incretin market includes: Mounjaro, Zepbound, Trulicity, semaglutide and liraglutide. SOURCE Eli Lilly and Company WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial StatementBiosimilar

03 Jan 2025

·endpts.com

Novo petitions FDA over Victoza compounding as first generic wins approval

Novo Nordisk is continuing its citizen petition crusade at the FDA, this time aiming to stop the compounding of Victoza, its blockbuster GLP-1. The push comes as the regulator late last month approved the first generic version of liraglutide from London-based Hikma Pharmaceuticals. The FDA said the generic approval was a priority since liraglutide and other GLP-1s are currently in shortage, which opens the door for compounders to step in. But Novo now insists, as it did in its citizen petition against semaglutide compounding in October, that the risks of allowing less-regulated compounders to make the drugs outweigh the benefits. “The safety issues raised by the use of compounded ‘liraglutide’ weigh against a finding of clinical need,” Novo wrote in the petition posted by the FDA on Thursday. “The impurity profiles and, in particular, the evidence of fibril formation in the unapproved ‘liraglutide’ products raise significant immunogenicity risks and pose serious threats to patients’ health.” The company pointed to an FDA database of unvetted adverse events that has documented 44 such events associated with compounded liraglutide since 2017. Of those, 38 involved “serious cases,” including one death. In June 2024, Teva launched an authorized generic of Victoza, kicking off the beginning of competition for the drug, which first won approval in 2010. At the time, Teva said IQVIA data showed Victoza had annual sales of about $1.7 billion as of April. Both Novo and Eli Lilly have launched legal campaigns against medical spas, weight loss clinics and compounding pharmacies marketing their own versions of the weight loss and diabetes drugs, though shortages of Lilly’s blockbuster GLP-1 tirzepatide were resolved last October in a move that could potentially cut off the compounders. “The entities currently mass-producing and mass-marketing compounded and counterfeit tirzepatide need to stop immediately,” Lilly said at the time.

Drug ApprovalBiosimilar

02 Jan 2025

·www.biopharmadive.com

Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

Happy New Year! We hope you had a restful holiday; If you took a break from keeping up with biotech news, weve got you covered with a brief rundown of the most important updates from the past week and a half.Pfizer wont move forward with asking regulators to approve a gene therapy for hemophilia A and instead will hand back rights to development partner Sangamo Therapeutics in a blow to the California-based biotechnology company. In a Dec. 30 statement, Sangamo CEO Sandy Macrae said his company was surprised and extremely disappointed by Pfizers decision, which comes some five months after the treatment met its goal in a Phase 3 study of people with the inherited bleeding disorder. Sangamo plans to search for an optimal path forward, which could include partnering with another company. Pfizer has steadily retreated from gene therapy, although it sells a hemophilia B gene therapy called Beqvez that it obtained from Spark Therapeutics. Ned PagliaruloRoche and Ideaya Biosciences acquired rights to similar, experimental lung cancer drugs in separate deals with China-based biotechnology companies. First, Ideaya on Monday paid Hengrui Pharma $75 million upfront for an antibody-drug conjugate that targets the protein delta-like ligand 3, or DLL3, and is currently in preclinical testing. Roche followed on Thursday by paying Innovent Biologics $80 million for a DLL3-targeting ADC that began a Phase 1 trial last month. Both drugs are being evaluated against small-cell lung cancer, a more aggressive and less common form of the disease. Ben FidlerAfter many years of effort, Novartis has obtained positive results from a Phase 3 study for a form of its spinal muscular atrophy gene therapy Zolgensma thats delivered via spinal injection rather than intravenous infusion. Data from the study, called Steer, showed treatment improved motor abilities in people with the neuromuscular disease who were two years of age or older and could still sit but had never walked independently. U.S. regulators suspended testing of the intrathecal formulation in late 2019 over safety concerns, but in August 2021 permitted Novartis to begin the Steer study. Novartis plans to share the new data with health authorities to support approval of the gene therapy in a broader range of people with spinal muscular atrophy. Ned PagliaruloBioNTech will pay the National Institutes of Health $792 million to settle disputes over use of patented technology to develop the mRNA COVID-19 vaccine Comirnaty, marketed by Pfizer, according to a securities filing.The payment will consist of $750 million worth of claimed royalties for the years 2020 through 2023 and $42 million for an amended license agreement that sets new royalty terms. Separately, BioNTech said it has settled with the University of Pennsylvania over patents related to technology used to develop Comirnaty, paying up to $467 million to Penn. Pfizer will reimburse BioNTech $365 million related to the NIH settlement and up to $170 million related to the Penn settlement. Jonathan GardnerAxsome Therapeutics intends to ask regulators for approval of a combination drug its developed to treat agitation caused by Alzheimers disease, despite mixed results from the companys latest late-stage trials. In one Phase 3 study, Axsomes drug, called AXS-05, lowered the risk of relapse in agitation versus placebo. However, AXS-05 missed its goal in another trial. Drawing on positive data from two prior studies, Axsome said it will submit a U.S. approval application in the second half of the year, which analysts expect may still be granted. Ned PagliaruloSanofi and partner SK Bioscience are expanding their partnership as they begin Phase 3 testing of a next-generation pneumococcal conjugate vaccine in children. The shot is designed to protect against 21 serotypes of Streptococcus pneumoniae and, according to Sanofi, is the first of its type targeting more than 20 to enter a Phase 3 trial in infants. The planned trial program will include over 7,700 infants, children and adolescents. If successful, the companies shot could eventually compete with Pfizers Prevnar 20, which in 2023 received a green light from the Food and Drug Administration for use in infants and children. Sanofi and SK Bioscience will co-fund research and development costs, while SK Bioscience will receive a 50 million euros upfront payment from Sanofi. Delilah AlvaradoThe Food and Drug Administration has approved Hikma Pharmaceuticals generic version of Novo Nordisks daily GLP-1 shot for diabetes, Victoza. First approved in 2010, Victoza once was the biggest selling drug in the class. But by 2023 its sales had declined to 8.7 billion kroner, or about $1.3 billion, while revenue from the more potent weekly GLP-1 shot Ozempic has grown since its 2017 launch. Teva Pharmaceutical launched an authorized generic of Victoza in June 2024. Jonathan Gardner '

Phase 3Drug ApprovalVaccineClinical ResultPhase 1

100 Deals associated with Liraglutide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Liraglutide	A10BJ02	DB06655

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Novo Nordisk, Inc.	23 Dec 2014
Overweight	US	Novo Nordisk, Inc.	23 Dec 2014
Diabetes Mellitus, Type 2	NO	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	EU	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	IS	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	LI	Novo Nordisk A/S	30 Jun 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 3	AR	Novo Nordisk A/S	01 Jun 2011
Obesity	Phase 3	IN	Novo Nordisk A/S	01 Jun 2011
Obesity	Phase 3	CH	Novo Nordisk A/S	01 Jun 2011
Obesity	Phase 3	IL	Novo Nordisk A/S	01 Jun 2011
Obesity	Phase 3	MX	Novo Nordisk A/S	01 Jun 2011
Obesity	Phase 3	RU	Novo Nordisk A/S	01 Jun 2011
Diabetes Mellitus, Type 2	Phase 3	MX	Novo Nordisk A/S	01 Feb 2006
Diabetes Mellitus, Type 2	Phase 3	PR	Novo Nordisk A/S	01 Feb 2006
Diabetes Mellitus, Type 2	Discovery	MX	Novo Nordisk A/S	01 Feb 2006
Diabetes Mellitus, Type 2	Discovery	PR	Novo Nordisk A/S	01 Feb 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	(maweagpyev) = ozqoqlveem inalthislw (xhumeunfko )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	(maweagpyev) = zzrcgttvrh inalthislw (xhumeunfko )
NCT04883346 (LBODP002, CTgov)	Phase 2	Obesity	34	liraglutide	dqmmgmhyoh(zsexnvyybi) = vjfswjqzfg zivengpjdt (ellgpqtyae, ahdtsfscvl - orvyoelkyo) View more	-	20 Nov 2024
Pubmed Manual	Not Applicable	Alcohol Use Disorder	227,866	Semaglutide	(hzwqeiwuim) = A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92) of AUD hospitalization. ftifmytlyl (mpbgknvitc ) View more	Positive	13 Nov 2024
				Liraglutide
NCT04199728 (CTgov)	Phase 1/2	Opioid-Related Disorders	27	Liraglutide Pen Injector (Investigational Group)	(vxjiqxuezb) = ulbqbogwhm awvjfypbeh (bmppwzckuv, bcxwcoshfl - vtiydzmgqu) View more	-	06 Nov 2024
				Placebo (Control Group)	(vxjiqxuezb) = zwxyuldmtz awvjfypbeh (bmppwzckuv, jnyxaeksaa - dmetxfmzlo) View more
NCT04775082 (SCALE Kids, Literature \| Pubmed \| N Engl J Med) Manual	Phase 3	Obesity	82	Liraglutide	(dyevishtuz) = nztvqrpkhk mxuijyykwj (cqranbrpkh ) View more	Positive	10 Sep 2024
				Placebo	(dyevishtuz) = knxouabdex mxuijyykwj (cqranbrpkh ) View more
NEWS Manual	Phase 2	Alzheimer Disease	204	Liraglutide	(cdqcgpbojk) = The trial’s primary endpoint was change in the cerebral glucose metabolic rate in the cortical regions of the brain, which was not met. itjnffjpev (wjlqyxwqjs ) Not Met View more	Positive	30 Jul 2024
				Placebo
NCT04531176 (EMPOWER-T2D, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Obesity	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	njesbtmqre(vmieacaakq) = xonymsbuhz qtvhbxsrwx (pbtdacfdua, vwnskmrguj - ulorchnsbg) View more	-	22 Jul 2024
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	njesbtmqre(vmieacaakq) = zqneyeczwh qtvhbxsrwx (pbtdacfdua, najfwzoekq - tuymvgjppq) View more
ADA2024 Manual	Not Applicable	Diabetes Mellitus, Type 2	159	fixed-ratio insulin degludec/liraglutide (Intervention regimen)	dxyyjqeafh(fckjkqjqub) = eibayrwtit zroxnfwhty (nhuuqprcap, 0.4) View more	Positive	21 Jun 2024
				Standard care	dxyyjqeafh(fckjkqjqub) = tjermltbez zroxnfwhty (nhuuqprcap, 0.6) View more
NCT03158805 (CTgov)	Phase 2	Bipolar Disorder \| Obesity	60	liraglutide (Active Drug)	cskvsmbhkg(ovyyedwmyn) = cgtpbwggne szfbogwziz (akuacnjygq, novbdamhhq - lfzwmtecvh) View more	-	27 Mar 2024
				Placebo (Placebo)	cskvsmbhkg(ovyyedwmyn) = yulrfnouwt szfbogwziz (akuacnjygq, kbsoyqlryf - uivlebyais) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis